NFKB1 and COVID-19: Hence, the release of IL-6, IL-17, and TNF-α, along with the increased activity of macrophages and neutrophils, cause the increased expression of PD-L1 on the surfaces of immune cells in COVID-19 (66), through the STAT3, PI3K/Akt and NF-κB pathways.